ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Acute Effects of Aerosolized S-Nitrosoglutathione in Cystic Fibrosis
dc.contributor.author | Snyder, Ashley H. | |
dc.contributor.author | McPherson, Marianne E. | |
dc.contributor.author | Hunt, John F. | |
dc.contributor.author | Stamler, Jonathan S. | |
dc.contributor.author | Gaston, Benjamin | |
dc.contributor.author | Johnson, Michael A. | |
dc.date.accessioned | 2014-12-16T20:06:16Z | |
dc.date.available | 2014-12-16T20:06:16Z | |
dc.date.issued | 2002-04-01 | |
dc.identifier.citation | Snyder, Ashley H. et al. (2002). "Acute Effects of Aerosolized S-Nitrosoglutathione in Cystic Fibrosis." American Journal of Respiratory and Critical Care Medicine, 165(7):922-926. http://www.dx.doi.org/10.1164/ajrccm.165.7.2105032 | |
dc.identifier.issn | 1073-449X | |
dc.identifier.uri | http://hdl.handle.net/1808/16125 | |
dc.description | This is the publisher's version, also available electronically from http://www.atsjournals.org/doi/abs/10.1164/ajrccm.165.7.2105032#.VJCPDXs4d41. | |
dc.description.abstract | S-Nitrosoglutathione (GSNO), a naturally occurring constituent of airway lining fluid, enhances ciliary motility, relaxes airway smooth muscle, inhibits airway epithelial amiloride-sensitive sodium transport, and prevents pathogen replication. Remarkably, airway levels of GSNO are low in patients with cystic fibrosis (CF). We hypothesized that replacement of airway GSNO would improve gas exchange in CF. In a double-blind, placebo controlled study, we administered 0.05 ml/kg of 10 mM GSNO or phosphate buffered saline by aerosol to patients with CF and followed oxygen saturation, spirometry, respiratory rate, blood pressure, heart rate, and expired nitric oxide (NO). Nine patients received GSNO and 11 placebo. GSNO inhalation was associated with a modest but sustained increase in oxygen saturation at all time points. Expired NO increased in the low ppb range with GSNO treatment, peaking at 5 minutes but remaining above baseline at 30 minutes. There were no adverse effects. We conclude that GSNO is well tolerated in patients with CF and improves oxygenation through a mechanism that may be independent of free NO. Further, GSNO breakdown increases expired NO. We suggest that therapy aimed at restoring endogenous GSNO levels in the CF airway may merit study. | |
dc.publisher | American Thoracic Society | |
dc.title | Acute Effects of Aerosolized S-Nitrosoglutathione in Cystic Fibrosis | |
dc.type | Article | |
kusw.kuauthor | Johnson, Michael A. | |
kusw.kudepartment | Chemistry | |
dc.identifier.doi | 10.1164/ajrccm.165.7.2105032 | |
kusw.oaversion | Scholarly/refereed, publisher version | |
kusw.oapolicy | This item does not meet KU Open Access policy criteria. | |
dc.rights.accessrights | openAccess |